In Brief: HemaSure
This article was originally published in The Gray Sheet
Executive Summary
HemaSure: President Steven Rouhandeh gains additional posts of chief executive officer and director effective Dec. 12. Rouhandeh succeeds Eugene Zurlo, who will remain as chairman of the board. HemaSure also announces that Edward Kelly, currently its president-medical devices, will assume the newly created titles of executive vice president and chief operating officer. Marlborough, Massachusetts-based HemaSure is in clinical trials for its SteriPath blood pathogen inactivation system; its LeukoNet Filter for leukocyte removal was 510(k) cleared in June of 1995...